Carmat Aktie

Carmat SA is a medtech that designs, manufactures and markets the Aeson artificial heart. It focuses on Aeson to make the first alternative to a heart transplant, and thus provide a therapeutic solution for people suffering from end-stage biventricular heart failure. The company was founded by Pouletty Philippe and Alain Carpentier on June 25, 2008 and is headquartered in Vélizy Villacoublay, France.